Does Rallies show 13F holders for PRAX?

Yes. Rallies tracks hedge fund and 13F ownership data for PRAX, including fund names, share counts, latest tracked quarter, and position changes when available.

Is PRAX research on Rallies investment advice?

No. Rallies provides research, data, and educational context for PRAX. It does not provide personalized investment advice.

PRAX (Praxis Precision Medicines, Inc. Common Stock) Stock Analysis - Hedge Fund Holdings

Praxis Precision Medicines, Inc. Common Stock (PRAX) is a publicly traded Healthcare sector company. As of May 20, 2026, PRAX trades at $335.76 with a market cap of $8.94B and a P/E ratio of -24.76. PRAX moved +4.66% today. Year to date, PRAX is +21.19%; over the trailing twelve months it is +745.37%. Its 52-week range spans $26.70 to $358.76. Analyst consensus is strong buy with an average price target of $643.38. Rallies surfaces PRAX's financials, insider trades, hedge fund holdings, congressional trades, analyst ratings, and AI-generated research below.

Who owns PRAX stock?

Hedge funds tracked by Rallies that own PRAX include Orbimed Advisors and Polen Capital. The latest tracked quarter is Mar 31, 2026. Rallies shows current holdings, share counts, position changes, and 13F ownership context for Praxis Precision Medicines, Inc. Common Stock.

PRAX Key Metrics

Key financial metrics for PRAX
Metric	Value
Price	$335.76
Market Cap	$8.94B
P/E Ratio	-24.76
EPS	$-13.48
Dividend Yield	0.00%
52-Week High	$358.76
52-Week Low	$26.70
Volume	230.75K
Avg Volume	0
Revenue (TTM)	$0
Net Income	$-303.27M
Gross Margin	0.00%

Top Hedge Funds Holding PRAX

Orbimed Advisors holds 172.50K shares of PRAX, changed +82.54% as of Mar 31, 2026.
Polen Capital holds 10.04K shares of PRAX, changed +0.00% as of Mar 31, 2026.

Latest PRAX News

Truist Initiates Praxis Coverage with $715 Target, 112% Upside and FDA NDA Acceptances — May 13, 2026
Praxis drops as it posts Q1 results and updates NDA/clinical milestones — May 7, 2026
PRAX slips 3% as investors de-risk ahead of May 7 Q1 results and conferences — May 5, 2026
PRAX climbs as FDA accepts ulixacaltamide NDA, sets Jan. 29, 2027 decision date — May 4, 2026
Praxis Precision Medicines rises as dual FDA NDA reviews keep catalysts in focus — May 1, 2026

Recent PRAX Insider Trades

Nemiroff Alex sold 1.71K (~$327.14K) on Nov 20, 2025.
Nemiroff Alex sold 13.34K (~$2.57M) on Nov 20, 2025.
Nemiroff Alex sold 977 (~$188.79K) on Nov 20, 2025.

PRAX Analyst Consensus

16 analysts cover PRAX: 0 strong buy, 14 buy, 1 hold, 1 sell, 0 strong sell. Consensus rating is strong buy. Average price target: $643.38.

Common questions about PRAX

Who owns PRAX stock?: Hedge funds tracked by Rallies that own PRAX include Orbimed Advisors and Polen Capital. The latest tracked quarter is Mar 31, 2026. Rallies shows current holdings, share counts, position changes, and 13F ownership context for Praxis Precision Medicines, Inc. Common Stock.
Does Rallies show 13F holders for PRAX?: Yes. Rallies tracks hedge fund and 13F ownership data for PRAX, including fund names, share counts, latest tracked quarter, and position changes when available.
Is PRAX research on Rallies investment advice?: No. Rallies provides research, data, and educational context for PRAX. It does not provide personalized investment advice.